Having trouble accessing articles? Reset your cache.

Nintedanib: Phase III data

Boehringer said nintedanib plus pemetrexed as second-line treatment of advanced non-squamous NSCLC met the primary endpoint of improving PFS vs. placebo plus pemetrexed in the double-blind, international Phase III LUME-Lung 2 trial even though enrollment

Read the full 356 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE